Valcote
Valcote Brand names, Valcote Analogs
- 2 PP (base)
- Alti-Valproic
- Bruceine D
- Convulex
- DPA
- DPA (VAN)
- Delepsine
- Depakene
- Depakine
- Deproic
- Di-n-propylacetic acid
- Di-n-propylessigsaure
- Dipropylacetic acid
- Dom-Valproic
- Epilex
- Epilim
- Epival
- Ergenyl
- Kyselina 2-propylvalerova
- Med Valproic
- Mylproin
- Myproic Acid
- Novo-Valproic
- Nu-Valproic
- PMS-Valproic Acid
- Penta-Valproic
- Pentanoic acid, 2-propyl-
- Propylvaleric acid
- Sodium hydrogen divalproate
- Sprinkle
- Valcote
- Valeric acid, 2-propyl-
- Valparin
- Valproate semisodique [French]
- Valproate semisodium
- Valproato semisodico [Spanish]
- Valproatum seminatricum [Latin]
- Valproic acid USP
- Valproic acid USP24
- Valproic acid semisodium salt (2:1)
- n-DPA
- n-Dipropylacetic acid
Valcote Brand Names Mixture
- No information avaliable
Valcote Chemical_Formula
C8H16O2
Valcote RX_link
http://www.rxlist.com/cgi/generic2/depakene.htm
Valcote fda sheet
Valcote msds (material safety sheet)
Valcote Synthesis Reference
Oberreit, Ber.29, 1998 (1896)
Valcote Molecular Weight
144.211 g/mol
Valcote Melting Point
120 - 130 oC
Valcote H2O Solubility
Slightly soluble (1.3 mg/mL)
Valcote State
Solid
Valcote LogP
2.549
Valcote Dosage Forms
Capsule (250 mg); Syrup (250 mg drug/5mL syrup)
Valcote Indication
For use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
Valcote Pharmacology
Valproic Acid is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder. It is also used to treat migraine headaches and schizophrenia. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome. Valproic Acid is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain. Valproic Acid dissociates to the valproate ion in the gastrointestinal tract. Valproic acid has also been shown to be an inhibitor of an enzyme called histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. A study published in August 2005 revealed that patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a 75% reduction in latent HIV infection.
Valcote Absorption
Rapid absorption from gastrointestinal tract.
Valcote side effects and Toxicity
Oral, mouse: LD50 = 1098 mg/kg; Oral, rat: LD50 = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems.
Valcote Patient Information
Since valproate products may produce CNS depression, especially when combined with another CNS depressant (eg, alcohol), patients should be advised not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.
Valcote Organisms Affected
Humans and other mammals
